174 related articles for article (PubMed ID: 15729584)
1. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
[TBL] [Abstract][Full Text] [Related]
2. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy.
Al Safarjalani ON; Zhou XJ; Naguib FN; Shi J; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2001 Nov; 48(5):389-97. PubMed ID: 11761457
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy.
Al Safarjalani ON; Zhou XJ; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2001 Aug; 48(2):145-50. PubMed ID: 11565561
[TBL] [Abstract][Full Text] [Related]
5. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
Ashour OM; Al Safarjalani ON; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2000; 45(5):351-61. PubMed ID: 10803917
[TBL] [Abstract][Full Text] [Related]
6. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
7. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy.
Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2000; 46(3):235-40. PubMed ID: 11021741
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
9. 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy.
Ashour OM; Naguib FN; el Kouni MH
Biochem Pharmacol; 1996 Jun; 51(12):1601-11. PubMed ID: 8687475
[TBL] [Abstract][Full Text] [Related]
10. 5-phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase.
el Kouni MH; Goudgaon NM; Rafeeq M; Al Safarjalani ON; Schinazi RF; Naguib FN
Biochem Pharmacol; 2000 Sep; 60(6):851-6. PubMed ID: 10930540
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
Pizzorno G; Yee L; Burtness BA; Marsh JC; Darnowski JW; Chu MY; Chu SH; Chu E; Leffert JJ; Handschumacher RE; Calabresi P
Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
[TBL] [Abstract][Full Text] [Related]
12. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Biochem Pharmacol; 2000 Sep; 60(5):687-92. PubMed ID: 10927027
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
14. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
Sommadossi JP; Cretton EM; Kidd LB; McClure HM; Anderson DC; el Kouni MH
Cancer Chemother Pharmacol; 1995; 37(1-2):14-22. PubMed ID: 7497584
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Ashour OM; Naguib FN; Khalifa MM; Abdel-Raheem MH; Panzica RP; el Kouni MH
Cancer Res; 1995 Mar; 55(5):1092-8. PubMed ID: 7866994
[TBL] [Abstract][Full Text] [Related]
16. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G
Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.
Ashour OM; Naguib FN; Panzica RP; Al Safarjalani ON; el Kouni MH
Biochem Pharmacol; 2000 Aug; 60(3):427-31. PubMed ID: 10856438
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Tourn E; Haenen GR; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Nov; 52(5):371-6. PubMed ID: 12898182
[TBL] [Abstract][Full Text] [Related]
20. [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice].
Wang GF; Zhang JY; Wu SY; Xu W; Wan SH; Shao CF; Zhang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Nov; 28(11):1993-5. PubMed ID: 19033111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
